CareDx's AlloSeq Tx 17 Awarded CE Mark Approval
CareDx, Inc. (Nasdaq: CDNA) has announced receiving CE mark approval for its AlloSeq Tx 17 technology, enhancing its availability for transplant patients, laboratories, and clinicians globally. This state-of-the-art solution offers superior donor organ matching and eliminates PCR disadvantages, improving workflow in Histocompatibility & Immunogenetics labs. Launched in September 2019, AlloSeq Tx 17 utilizes next-generation Hybrid Capture technology for HLA testing. CareDx aims to enhance patient care with genomics-based information, reinforcing its leadership in precision medicine for transplant solutions.
- CE mark approval for AlloSeq Tx 17 expands market access for transplant solutions.
- AlloSeq Tx 17 offers improved donor organ matching with next-generation technology.
- Elimination of PCR disadvantages enhances lab workflow and data reliability.
- None.
SOUTH SAN FRANCISCO, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it had received the CE mark approval for AlloSeq Tx 17, making it broadly available to transplant patients, laboratories and clinicians around the world.
AlloSeq Tx 17 is the best in class solution for matching transplant donor organs to recipients, utilizing next generation Hybrid Capture technology for HLA testing. CareDx launched this novel technology during the American Society for Histocompatibility and Immunogenetics (ASHI) and BANFF Foundation for Allograft Pathology's Joint meeting September 2019.
"AlloSeq Tx 17 eliminates PCR disadvantages such as allele drop out and provides a simple workflow that could be easily implemented in Histocompatibility & Immunogenetics laboratories. Generation of reliable data and ability to extend the typing to additional non-classical HLA loci will provide better care for patients," said Milena Ivanova-Shivarova, Lab Manager, Alexandrovska University Hospital.
"CareDx is committed to providing best-in-class solutions for transplant patients. AlloSeq Tx 17 highlights CareDx's position as a leading provider of genomics-based information in transplantation, and brings significant advantages to clinicians and patients across the transplant journey," said David Sayer, PhD, VP Global Transplant Laboratory Solutions.
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
CONTACTS:
Sasha King
Chief Marketing Officer, CareDx Inc.
415-287-2393
sking@caredx.com
Investor Relations
Greg Chodaczek
347-620-7010
investor@caredx.com
